星華反光(301077.SZ):擬使用部分超募資金建功能型面料、膠粘劑及研發中心項目
格隆匯12月30日丨星華反光(301077.SZ)公佈,公司此次投資建設項目預計投資總額為85352.14萬元,其中擬使用部分超募資金總計4億元,其中:
(1)年產15000萬平方米功能型面料生產項目預計總投資額33017.69萬元,擬使用部分超募資金1.5億元;
(2)年產50000噸膠粘劑項目預計總投資額22001.15萬元,擬使用部分超募資金1億元;
(3)功能性材料、面料生產研發中心項目預計總投資額30333.3萬元,擬使用部分超募資金1.5億元。
剩餘部分由公司自有資金或通過其他融資方式解決。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.